Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A GINECO/GCIG Randomized Clinical Trial
暂无分享,去创建一个
O. Trédan | V. D’Hondt | A. Zannetti | F. Tinquaut | L. Venat-Bouvet | E. Pujade-Lauraine | J. Herrstedt | D. Lorusso | G. Freyer | A. Lortholary | C. Falandry | E. Bourbouloux | L. Mourey | E. Malaurie | F. Rousseau | P. Brachet | A. Savoye | R. Sverdlin | L. Stefani | Marie-AngeMouret-Reynier | V. D'Hondt
[1] Ftlo Bonin-Cecelia,et al. Phase II: , 2020, The Power of Accountability.
[2] F. Guyon,et al. Management of epithelial cancer of the ovary, fallopian tube, primary peritoneum. Long text of the joint French clinical practice guidelines issued by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY, endorsed by INCa. (Part 2: systemic, intraperitoneal treatment, elderly patients, fertility preservation, foll , 2019, Journal of gynecology obstetrics and human reproduction.
[3] H. Donovan,et al. Chemotherapy in older adult gynecologic oncology patients: Can a phenotypic frailty score predict tolerance? , 2019, Gynecologic oncology.
[4] L. V. van Huis-Tanja,et al. Treatment decision-making in elderly women with ovarian cancer: an age-based comparison , 2019, International Journal of Gynecologic Cancer.
[5] A. Gadducci,et al. Ovarian Cancer in Elderly Patients: Patterns of Care and Treatment Outcomes According to Age and Modified Frailty Index , 2017, International Journal of Gynecologic Cancer.
[6] A. Weaver,et al. Functional not chronologic age: Frailty index predicts outcomes in advanced ovarian cancer. , 2017, Gynecologic oncology.
[7] G. Scambia,et al. Ovarian Cancer Management in the Oldest Old: Improving Outcomes and Tailoring Treatments , 2017, Aging and disease.
[8] A. Secord,et al. Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study. , 2017, Gynecologic oncology.
[9] P. Viens,et al. Prognostic Factors for Ovarian Epithelial Cancer in the Elderly: A Case-Control Study , 2015, International Journal of Gynecologic Cancer.
[10] B. Weber,et al. Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] B. V. van Munster,et al. Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review. , 2012, The Lancet. Oncology.
[12] Kathleen M. Fairfield,et al. Completion of adjuvant chemotherapy and use of health services for older women with epithelial ovarian cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] A. Tinker,et al. Clinical Trials and Treatment of the Elderly Diagnosed With Ovarian Cancer , 2011, International Journal of Gynecologic Cancer.
[14] D. Lacombe,et al. EORTC elderly task force position paper: approach to the older cancer patient. , 2010, European journal of cancer.
[15] S. Pignata,et al. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study. , 2008, Critical reviews in oncology/hematology.
[16] A. Fader,et al. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients. , 2008, Gynecologic oncology.
[17] D. Levine,et al. Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy. , 2007, Gynecologic oncology.
[18] B. Weber,et al. Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] S. Loibl,et al. Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged >or=70 years with advanced ovarian cancer--a study by the AGO OVAR Germany. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] B. Weber,et al. Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] M. Janssen-Heijnen,et al. The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study. , 2005, Gynecologic oncology.
[22] A. Neugut,et al. Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer. , 2004, Gynecologic oncology.
[23] P. DiSilvestro,et al. Comparison of tolerance of combination carboplatin and paclitaxel chemotherapy by age in women with ovarian cancer. , 2002, Gynecologic oncology.
[24] A. Fishman,et al. Age contrasts in clinical characteristics and pattern of care in patients with epithelial ovarian cancer. , 2002, Gynecologic oncology.
[25] I. Tannock,et al. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial , 2002, The Lancet.
[26] A. Gadducci,et al. Gynecological malignancies in elderly patients: is age 70 a limit to standard-dose chemotherapy? An Italian retrospective toxicity multicentric study. , 2002, Gynecologic oncology.
[27] A. Rademaker,et al. Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: an Illinois Cancer Center study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .